DarioHealth Future Growth

Future criteria checks 2/6

DarioHealth is forecast to grow earnings and revenue by 9.2% and 28.1% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be 4.4% in 3 years.

Key information

9.2%

Earnings growth rate

17.8%

EPS growth rate

Healthcare Services earnings growth	31.0%
Revenue growth rate	28.1%
Future return on equity	4.4%
Analyst coverage	Low
Last updated	12 Nov 2024

Recent future growth updates

Recent updates

Slammed 25% DarioHealth Corp. (NASDAQ:DRIO) Screens Well Here But There Might Be A Catch

Nov 17

A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb

Oct 03

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 30% Lower

Aug 09

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

May 31

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Feb 16

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

Nov 06

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Oct 07

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Aug 16

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

Aug 15

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 13

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

Oct 05

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Aug 24

DarioHealth Q2 2022 Earnings Preview

Aug 12

DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future

Jul 29

Earnings and Revenue Growth Forecasts

NasdaqCM:DRIO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	47	-34	-13	-8	2
12/31/2025	37	-32	-11	-6	3
12/31/2024	27	-42	-20	-23	2
9/30/2024	23	-32	-39	-39	N/A
6/30/2024	19	-36	-41	-40	N/A
3/31/2024	19	-49	-39	-39	N/A
12/31/2023	20	-55	-31	-30	N/A
9/30/2023	24	-57	-32	-31	N/A
6/30/2023	27	-58	-33	-33	N/A
3/31/2023	27	-58	-35	-35	N/A
12/31/2022	28	-60	-48	-48	N/A
9/30/2022	27	-65	-56	-55	N/A
6/30/2022	26	-73	-57	-57	N/A
3/31/2022	25	-72	-58	-58	N/A
12/31/2021	21	-68	-51	-50	N/A
9/30/2021	17	-58	-42	-42	N/A
6/30/2021	13	-43	-34	-33	N/A
3/31/2021	10	-32	-24	-24	N/A
12/31/2020	8	-33	-18	-18	N/A
9/30/2020	7	-31	-14	-14	N/A
6/30/2020	7	-26	-13	-13	N/A
3/31/2020	7	-27	-16	-16	N/A
12/31/2019	8	-21	-16	-16	N/A
9/30/2019	7	-19	-16	-16	N/A
6/30/2019	7	-20	-16	-16	N/A
3/31/2019	8	-21	-13	-13	N/A
12/31/2018	7	-18	-12	-11	N/A
9/30/2018	7	-17	-11	-10	N/A
6/30/2018	7	-16	N/A	-10	N/A
3/31/2018	6	-14	N/A	-10	N/A
12/31/2017	5	-16	N/A	-11	N/A
9/30/2017	4	-16	N/A	-10	N/A
6/30/2017	4	-14	N/A	-10	N/A
3/31/2017	3	-14	N/A	-9	N/A
12/31/2016	3	-12	N/A	-8	N/A
9/30/2016	2	-9	N/A	-9	N/A
6/30/2016	2	-10	N/A	-7	N/A
3/31/2016	1	-8	N/A	-7	N/A
12/31/2015	1	-7	N/A	-6	N/A
9/30/2015	1	-9	N/A	-7	N/A
6/30/2015	0	-14	N/A	-7	N/A
3/31/2015	0	-15	N/A	-8	N/A
12/31/2014	0	-16	N/A	-9	N/A
9/30/2014	N/A	-13	N/A	-8	N/A
6/30/2014	N/A	-10	N/A	-9	N/A
3/31/2014	N/A	-12	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DRIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DRIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DRIO's revenue (28.1% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: DRIO's revenue (28.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DRIO's Return on Equity is forecast to be low in 3 years time (4.4%).

DarioHealth Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 21% to US$3.83

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 21%, EPS upgraded

Consensus EPS estimates fall by 11%, revenue upgraded

Consensus revenue estimates decrease by 16%, EPS upgraded

Consensus EPS estimates upgraded to US$1.71 loss, revenue downgraded

Recent updates

Slammed 25% DarioHealth Corp. (NASDAQ:DRIO) Screens Well Here But There Might Be A Catch

Third quarter 2024 earnings: EPS exceeds analyst expectations

DarioHealth Corp., Annual General Meeting, Dec 18, 2024

DarioHealth Corp. to Report Q3, 2024 Results on Nov 07, 2024

A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb

DarioHealth Corp. Receives A Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Price target decreased by 21% to US$3.83

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 21%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 30% Lower

DarioHealth Corp. to Report Q2, 2024 Results on Aug 08, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

DarioHealth Corp. Announces Management Changes

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%, EPS upgraded

DarioHealth Corp. to Report Q1, 2024 Results on May 15, 2024

DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Consensus EPS estimates upgraded to US$1.71 loss, revenue downgraded

DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

Consensus EPS estimates fall by 29%

Full year 2023 earnings released: US$2.24 loss per share (vs US$2.54 loss in FY 2022)

DarioHealth Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024

DarioHealth Corp. announced that it has received $22.422 million in funding

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Consensus revenue estimates fall by 18%

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.70 loss in 3Q 2022)

DarioHealth Corp. to Report Q3, 2023 Results on Nov 02, 2023

DarioHealth Corp., Annual General Meeting, Dec 11, 2023

New minor risk - Share price stability

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DarioHealth Corp. to Report Q2, 2023 Results on Aug 10, 2023

DarioHealth Corp. Announces the Presentation of Research at the American Diabetes Association 83(rd) Scientific Sessions

Price target decreased by 13% to US$10.20

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

DarioHealth Corp. announced that it has received funding

DarioHealth Corp. to Report Q1, 2023 Results on May 11, 2023

Consensus EPS estimates upgraded to US$1.75 loss, revenue downgraded

Full year 2022 earnings released: US$2.70 loss per share (vs US$4.75 loss in FY 2021)

DarioHealth Corp. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

DarioHealth Corp. Announces Termination of Dror Bacher, Chief Operating Officer

DarioHealth Corp. Announces Matt Alberico as Senior Vice President of Growth

Independent Director notifies of intention to sell stock

Price target decreased to US$15.02

High number of new and inexperienced directors

DarioHealth Corp. to Report Q3, 2022 Results on Nov 14, 2022

DarioHealth Corp., Annual General Meeting, Dec 07, 2022

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

DarioHealth Corp. Publishes New Clinical Research Linking the Use of Its Biofeedback Device to Reduced Back Pain

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$16.64

DarioHealth Q2 2022 Earnings Preview